Deregulated anti-apoptotic proteins Bc1-2 and Bcl-xL have been shown to function as oncoproteins in the development of androgen-independent prostate cancer
and chemoresistance in prostate cancer (Catz and Johnson 2003; Lebedeva et al.
Evidence for clonal outgrowth of androgen-independent prostate cancer
cells from androgen-dependent tumors through a two-step process.
Molecular biologyof androgen-independent prostate cancer
: the role of the androgen receptor pathway.
Role of coordinated molecular alterations in the development of androgen-independent prostate cancer
: an in vitro model that corroborates clinical observations.
Of the 80 patients completing 1 treatment cycle, there were no cases of androgen-independent prostate cancer
Lycopene Treatment Induced Significant Demethylation of the GSTP1 Promoter in a Human Androgen-Independent Prostate Cancer
Derived PC-3 Cell Line.
Cretu et al., "Proteomic profiling of androgen-independent prostate cancer
cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer," Journal of Biological Chemistry, vol.
(17) A proprietary form of modified citrus pectin (MCP) was shown to interrupt and reduce the metastatic process by reducing migration, adhesion, and invasion in both the androgen-independent prostate cancer
PC-3 line, and in the aggressive breast cancer triple negative cell line, MDA-MB-231.
These results have been recently confirmed in androgen-dependent and androgen-independent prostate cancer
The phase III Immunotherapy for Prostate AdenoCarcinoma Treatment (IMPACT, 9902B) study is an ongoing, double-blind, placebo-controlled special protocol assessment trial testing Provenge (sipuleucel-T) in 512 men with metastatic, androgen-independent prostate cancer
. Although full data remain blinded, Dendreon Corp., the Seattle biotech developing the vaccine, reported a 20% reduction in the risk of death in the treatment arm, compared with the placebo arm, at 24 months (hazard ratio = 0.80).
A phase I/II study of VELCADE in combination with docetaxel, being led by Robert Dreicer, M.D., at the Cleveland Clinic Foundation, Cleveland, OH, examined the dose-limiting toxicities, maximum tolerated dose, and the effects on PSA levels of VELCADE and docetaxel, both given weekly for two out of three weeks, in patients with advanced androgen-independent prostate cancer
. Two dose levels were expanded into phase II cohorts, one with VELCADE 1.3mg/m2 and docetaxel 40 mg/m2, the second with VELCADE 1.6mg/m2 and docetaxel 40 mg/m2.
The over-expression is thought to reflect androgen-independent prostate cancer